Cara Therapeutics has recently resumed clinical trials for its novel kappa opioid receptor agonist CR845 in managing acute and chronic pain. After the FDA clinical hold on CR845 for postoperative pain was removed in late April 2016, Cara Therapeutics has resumed patient enrollment in several clinical trials.
Dr. Joe Stauffer, Chief Medical Officer, Cara Therapeutics, will be presenting the latest post-operative and chronic pain data at the 10th Annual Pain & Migraine Therapeutics Summit. Dr. Stauffer will also be presenting an informative review of the kappa opioid class, and the human abuse liability data of CR845. For more information, visit: http://paintherapeuticsummit.com.
CR845 is a peripherally acting kappa opioid receptor agonist being investigated in managing acute and chronic pain. In Phase 2 trials, CR845 treatment showed significant reductions in both pain and opioid-related side effects. Cara Therapeutics will quickly resume the CLIN3001 adaptive Phase 3 trial of I.V. CR845 for postoperative pain. For the latest information on CR845, visit: http://www.caratherapeutics.com/index.shtml.
The 10th Annual Pain & Migraine Therapeutics Summit is the US's premier pain conference covering the field of pain research and therapeutics. With various stakeholders in pharmaceutical, biotech, device and medical communities attending, this conference will provide multi-faceted perspectives on the latest pain research. For more information, please download a brochure at: http://paintherapeuticsummit.com/index.php/brochure.
For more information, please contact:
John Waslif: Managing Director
Arrowhead Publishers
866-945-0263 ext 700
john.waslif@arrowheadpublishers.com
Rachel Donlon: Marketing Associate
Arrowhead Publishers
866-945-0263 ext 701
Rachel.donlon@arrowheadpublishers.com